Kelyniam Global, Inc. (KLYG) research, news, and more from GeoInvesting

Company description

Sat, 24 May 2008 04:00:00 GMT

We are an engineering and management consulting company providing services for, but not limited to, large scale manufacturing industries. Our clients are typically in the aircraft and automotive industries. We offer a complete cradle to grave consulting service that encompasses all disciplines of the Design, Engineering and Manufacturing process which specializes in the use of CADCAM (Computer aided design computer aided manufacturing). We have recently begun investigating the use of CADCAM technology in the medical industries. The company believes that with our expertise with high tolerance manufacturing, we can assist the medical industry in providing a better product to patients by the use of Bio-CADCAM technology.

(May 2, 2008)

Research

Mon, 16 Mar 2026 21:16:19 GMT

Kelyniam Global, Inc. (OOTC:KLYG) ($0.09; $4.6M market cap) announced Q4 and full-year 2025 results:

Q4 sales of $866,731 vs. $835,777 in the prior year
Q4 2025 EPS: $0.00 vs. $0.00 in the prior year
FY 2025 sales of $3,053,222 vs. $3,328,384 in the prior year
FY 2025 EPS: loss of $(0.00) vs. $0.00 in the prior year
The company received FDA 510(k) clearance for Fusion™ cranial and craniofacial implants using VESTAKEEP® Fusion biomaterial.
Board rejected unsolicited acquisition interest, citing preliminary valuation as materially inadequate relative to company assets and long-term growth potential.

Management Commentary:

"Despite a challenging start to last year, our team delivered a strong rebound in the second half while achieving meaningful bottom-line progress through continued expense management," said Ross Bjella, CEO of Kelyniam Global. "We are especially pleased with the 85% improvement in net loss, reflecting the strength of our core business model, the elimination of prior-year one-time charges, and sales across our innovative product portfolio. These results demonstrate our ability to respond to market conditions and we remain confident in our path forward."

Our Quick Take:

So far, we are disappointed in management's execution of the growth strategies it outlined during a Fireside Chat Skull Session in January 2025. We are also concerned that the company has already burned through the cash it raised at the end of 2024, partly due to accelerated marketing efforts that included hiring additional sales representatives.

You can watch that here.

That said, we would like to fully understand the growth opportunity related to the company’s FDA 510(k) clearance for Fusion™ cranial and craniofacial implants using VESTAKEEP® Fusion biomaterial.

We plan to revisit the Skull Session, where management discussed how additional FDA approvals could substantially expand its addressable market. It appears this progress has taken longer than expected. As a result, it may be a good time to invite the company back for another Skull Session to provide an update.

Kelyniam Global, Inc. designs, manufactures, and distributes custom cranial and maxillofacial implants using advanced computer-aided design and medical-grade polymers for reconstructive surgical applications.

Research

Tue, 11 Nov 2025 22:08:13 GMT

Kelyniam Global, Inc. (OTC:KLYG) ($0.19; $9.4M market cap) announced Q3 2025 results:

Q3 sales of 0.82 million vs. 0.78 million in the prior year
Q3 2025 loss per share: $0.00 vs. a loss of $0.00 in the prior year
FDA Clearance: Received 510(k) clearance for Vestakeep®, a resorbable bi-calcium phosphate implant for craniofacial reconstruction.
Hospital Approvals Pipeline: Product line under Value Analytics review at six major U.S. hospitals, including two Level 1 trauma centers, potentially adding $500,000+ in annual recurring revenue.
OTC Market Uplisting: KLYG uplisted to OTCID status, signaling greater transparency and compliance.

Management Commentary:

"Sales have faced headwinds this year from a slow distributor ramp-up and temporary market share shifts, but through Q3, we're steadily catching up to 2024 levels and building a stronger foundation for sustainable growth," said Ross Bjella, CEO of Kelyniam Global. "The cranial implant sector remains robust, with competitors with overall market projections showing expansion from $1.43 billion in 2024 to over $1.5 billion in 2025. We're capitalizing on this by aggressively adding distributors in untapped markets, where we see tremendous opportunity to capture demand for our rapid-turnaround, custom solutions."

Research

Mon, 12 May 2025 14:37:46 GMT

Kelyniam Global, Inc. (OTC:KLYG) ($0.15; $4.60M market cap) announced Q1 2025 results:

Q1 sales of $0.62 million vs. $0.96 million in the prior year
Q1 EPS of $(0.00) vs $0.00 in the prior year
Operating loss of $(140,556) vs. operating profit of $123,599 in Q1 2024
New three-year U.S. distribution agreement with Osteopore Ltd. (ASX: OSX)

Management Commentary:

“Kelyniam experienced a challenging first quarter due to seasonal variability and the timing of surgical schedules, which delayed revenue recognition,” said Ross Bjella, CEO of Kelyniam. “To address these challenges, we strengthened our sales organization by appointing Alex Rivero as National Sales Director and plan to onboard up to 10 additional distributors in 2025. Our commitment to delivering custom implants within 24-48 hours, combined with strategic partnerships, positions us for improved performance.”

“Our partnerships with Osteopore and Finceramica position Kelyniam as a leader in regenerative medicine in the U.S.,” added Bjella. “Regenerative products are an important part of the future of cranial surgery and will uniquely position Kelyniam in the market along with our commitment to quality and rapid service.”

Desiree Webb, Kelyniam's Chief Operating and Revenue Officer said, “Osteopore's products are exceptional additions for surgeons in need of a biomimetic and bioresorbable option for areas where natural, healthy bone growth are desired. Kelyniam is laser focused on providing the best in cranial and craniofacial regenerative options, and we look forward to making great strides with Osteopore in the United States. Osteopore will complement Kelyniam's culture of providing a high level of service and expertise for the most complex cases by leveraging key opinion leaders in various surgical specialties.”

Osteopore's CEO, Dr. Yujing Lim said, “Kelyniam has demonstrated its ability to manufacture and distribute effectively, as shown by their record performance in 2024. We believe that working directly with Kelyniam allows us to leverage their established access to hospitals and potential customers, thereby accelerating customer access to Osteopore's products.”

Research

Mon, 17 Mar 2025 20:54:06 GMT

Kelyniam Global (OOTC:KLYG) ($0.014; $4.4M market cap) announced Q4 2024 results:

Q4 sales of $830K vs $930K in the prior year
Q4 non-gaap net loss of $120K vs non-gaap income of $100k in the prior year
Full year sales of $3.3 million vs $2.6 million
Full year non-GAAP net income of $211k vs a loss of $365k

You can reference our call from January 2025 with management for the company’s growth outlook, which inferred Q4 revenue growth would be flat. It appears that Q4 2024 may have been impacted by FDA compliance measures the company took in the quarter. We are mildly disappointed that the company did not maintain profitability in the quarter. However, we presume extra expenses were associated with this task, something we will try to confirm with management.

“Completion of an FDA audit late last year resulting in 5 minor observations, all of which have been addressed”

With a dilutive raise behind them, 2025 will be a pivotal year to see if the company can deploy that capital to drive sales growth and remain consistently profitable.

Research

Mon, 03 Feb 2025 17:03:07 GMT

In our weekly update, we added KLYG to our Run To One Dollar Model Portfolio.

New Run to $1 (R21) Model Portfolio Addition: We are adding a niche medical device company, Kelyniam Global, Inc. (OOTC:KLYG), to our Run to One (R21) Model Portfolio, which is defined as a portfolio of stocks trading under $1 that we believe have a good chance of eclipsing the $1 mark in the future.
Under-the-Radar Growth Story: Management believes the company’s specialized products, rapid manufacturing capabilities, and disciplined financial execution give it a competitive edge in a traditionally slow-moving industry.
Scaling Without Dilution: After achieving three consecutive profitable quarters and a 20% revenue increase, the company recently raised capital—not for survival, but to expand sales efforts without needing further dilution.
Potential Multi-Bagger: With a product that has clear competitive advantages, expanding margins, and an attractive valuation, we believe significant upside exists, including being an acquisition target in the future.

See the full reasoning here. (As well as last week’s full conversation with the executive management team, here.

Research

Mon, 11 Nov 2024 05:00:00 GMT

Kelyniam Global (OOTC:KLYG) ($0.014; $4.4M market cap) announced Q3 2024 results:

Q3 sales of $790K vs $640K in the prior year
Q3 operating profit of $101K vs a loss of $100k in the prior year
Nine month sales of $2.49 million vs $1.34 million
Nine month operating profit of $273,248 vs a loss of $329,993

"We are proud of our profitable growth in 2024," said Bjella. "Our team has been invigorated by rising sales, the addition of new surgeons and hospital customers, and a stringent focus on expense management. These results support Kelyniam's capability to generate cash and capitalize on our operating model's leverage. While pricing pressures persist, strategic growth and diligent expense management have driven the significant turnaround in our operating profit."

Other events occurring in the third quarter included:

Greater market acceptance for the CustomizedBoneÔ (hydroxyapatite) regenerative implant
Greater trial and usage of the NEOS Cranial Loop fixation
Attendance at the College of Neurological Surgeons annual meeting

Kelyniam Inc., specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers. The Company develops, manufactures, and distributes custom cranial and maxillo-facial implants for patients.

Research

Mon, 12 Aug 2024 17:52:23 GMT

Kelyniam Global (OOTC:KLYG) ($0.012; $3.6M market cap) announced Q2 2024 results:

Q2 sales of $743K vs $544K in the prior year
Q2 operating profit of $49K vs a loss of $162k in the prior year
Six month sales of $1.7 million vs $1.1 million
Six month operating profit of $172,093 vs a loss of $229,345

“The increase in profitability was primarily due to increased sales, efficiency improvements and reducing software, insurance and consulting expenses. Sales for the first half of the year have remained strong as additional surgeons request implants with Kelyniam's patented integrated fixation in the PEEK implant product line. Sales from the hydroxyapatite CustomizedBone™ implant with NEOS Cranial Loop fixation also increased as the products continue to gain market acceptance.”

Research

Tue, 14 May 2024 18:30:47 GMT

Kelyniam Global (OOTC:KLYG) ($0.04; $1.2M market cap) announced Q1 2024 results:

Q4 sales of $957,447 vs $596,455 in the prior year
Operating profit of $123,599 vs a loss of $67,978 in the prior year

“Profitability was strongly enhanced by a year's long effort in reconfiguring the Company's structural costs and a tight focus on this year's operations. The Company saw those efforts pay off with decreased consulting fees and information technology costs which positively affected the bottom line.”

"Sales momentum from Q4 continued into Q1, resulting in record growth, quarterly revenue and profit. Surgeons and Distributors using Kelyniam custom cranial and craniofacial implants have increased, in addition to the level of case complexity. This is a result of proven outcomes, a laser focus on customer service and operations, and Kelyniam's ability to deliver RUSH cases within 24-48 hours to any hospital in the United States. Interest in the CustomizedBoneä hydroxyapatite osteo-integrative cranial implant continues to grow, particularly due to the indication for pediatric patients. Looking forward we expect to see continued interest in this unique cranial implant because of the recent approval of the NEOS Cranial Loop fixation vs. traditional suturing, resulting in decreased OR time."

Research

Mon, 18 Mar 2024 14:44:28 GMT

Kelyniam Global (OOTC:KLYG) ($0.05; $1.4M market cap) announced Q4 2023 results:

Q4 sales of $930,000 vs $820,000 in the prior year
Net income of $196,000 vs $34,000 in the prior year

"The company set a quarterly unit sales record in the fourth quarter which contributed to achieving slight unit volume growth over 2022," said Ross Bjella, Kelyniam's CEO. "While we were pleased with the increased sales momentum late in the year, total revenue was down 12% on the year due to management focusing on strategic investments in personnel and infrastructure in the early part of the year."

Events that significantly affected the year and 4th quarter included:

Unit growth was up 40% over the previous quarter.
A major competitor pulled their implant from the market, opening an opportunity for increased PEEK and CustomizedBoneä sales.
The company added 5 new sales representatives as distributor partners